18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription.

Johannes H A M Kaanders, Johan Bussink, Erik H J G Aarntzen, Pètra Braam, Heidi Rütten, Richard W M van der Maazen, Marcel Verheij, Sven van den Bosch

Seminars in radiation oncology 2023 Jul

filter terms:

PET imaging with 2'-deoxy-2'-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed. Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Citation

Johannes H A M Kaanders, Johan Bussink, Erik H J G Aarntzen, Pètra Braam, Heidi Rütten, Richard W M van der Maazen, Marcel Verheij, Sven van den Bosch. 18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription. Seminars in radiation oncology. 2023 Jul;33(3):287-297